Twenty-seven states and the District of Columbia have filed a lawsuit in bankruptcy court seeking to block the sale of ...

Twenty-seven states and the District of Columbia have filed a lawsuit in bankruptcy court seeking to block the sale of ...

Me is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, ...

Bankrupt genetic testing company 23andMe told a U.S. bankruptcy judge on Wednesday that it wants to re-open bidding on its ...

Me has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing ...

States argue that biological samples, DNA data, health-related traits and medical records are too sensitive to be sold without each person's express, informed consent.

Twenty-seven states and the District of Columbia on Monday filed a lawsuit in bankruptcy court seeking to block the sale of ...

The move marks a turning point in 23andMe’s tumultuous decline. Founded in 2006 by Wojcicki, the company initially gained traction with its saliva-based ancestry kits and went public in 2021. By the ...

Bankrupt genetic analysis company 23andMe will hold a second auction for its cache of DNA data with an opening bid of $305 ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services. By Michael Levenson 23andMe, the genetic ...

Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million.